Dock-and-Lock PEGylation for Site-Specific Monoconjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PEGylation methods often result in mixtures of mono- and multi-PEGylated conjugates, making it difficult to achieve site-specific attachment of a single PEG chain to a therapeutic agent, which can affect bioavailability and bioactivity.
Innovation Solution
The Dock-and-Lock (DNL) method utilizes specific protein-protein interactions between dimerization and docking domains (DDD) and anchor domains (AD) to form a stable complex, allowing site-specific attachment of a single PEG chain to a predetermined location on a therapeutic agent, using disulfide bonds for stabilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional PEGylation methods are used to attach PEG to therapeutic agents, then PEGylation efficiency is improved, but site-specificity deteriorates resulting in mixtures of mono- and multi-PEGylated conjugates
Solution Approach 1:
The patent introduces a docking domain (DDD) and anchor domain (AD) system that pre-organizes the therapeutic agent and PEG reagent into a specific geometric arrangement before the actual PEGylation reaction occurs. This preliminary positioning ensures that only the N-terminal alpha amino group can access the PEG reagent, preventing modification at other sites and eliminating the formation of multi-PEGylated conjugates while maintaining high reaction efficiency.
Solution Approach 2:
The patent creates a localized reactive environment by designing the DDD-AD complex where the PEG reagent is spatially restricted to interact only with the N-terminal alpha amino group of the therapeutic agent. This local confinement of the reaction to a specific site on the protein ensures site-specific PEGylation while maintaining high productivity through the pre-organized transition state.
2Duration of action of moving object
If multiple PEG chains are attached to therapeutic agents, then serum half-life is extended, but bioactivity is reduced due to steric hindrance and conformational changes
Solution Approach 1:
By pre-organizing the DDD-AD complex and restricting PEG attachment to the N-terminal position, the patent ensures that only a single PEG chain is attached at a predetermined location. This preliminary positioning prevents the formation of multi-PEGylated conjugates that would cause steric hindrance, while still providing sufficient serum half-life extension through the single PEG attachment.
Solution Approach 2:
The patent concentrates the PEGylation effect at a single local site (the N-terminus) rather than distributing multiple PEG chains across multiple sites on the protein. This localized approach maintains the overall conformation and bioactivity of the therapeutic agent while still achieving the desired pharmacokinetic improvement through the single PEG attachment.
3Manufacturing precision
If site-specific PEGylation is achieved through chemical modification, then manufacturing precision is improved, but process complexity increases due to additional purification steps
Solution Approach 1:
The patent incorporates the docking domain and anchor domain directly into the therapeutic agent and PEG reagent structures before the PEGylation reaction. This preliminary integration of the site-specificity mechanism into the molecular structures themselves eliminates the need for complex external purification systems, as the DDD-AD complex inherently directs the reaction to the correct site and facilitates easy separation of the desired product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach produces monoPEGylated conjugates with significantly slower clearance from serum, maintaining or enhancing bioactivity, and allows for longer-lasting therapeutic effects, enabling less frequent dosing schedules.
Implementation Method 1
specific protein-protein interactions between dimerization and docking domains (DDD) and anchor domains (AD)
Implementation Method 2
using disulfide bonds for stabilization
Data Source
AI summary
The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.